Evidence map›Paper›PMID 22988082›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2012

Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes.

Johanneke Kleinnijenhuis, Jessica Quintin, Frank Preijers, Leo A B Joosten, Daniela C Ifrim, Sadia Saeed, Cor Jacobs, Joke van Loenhout, Dirk de Jong, Hendrik G Stunnenberg and 4 more

10 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 10 registered trials, which are not on this map. Cited by 990 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
990citing papers in PubMed, 3 pooled it
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02085590 phase2 / phase3completednot on this mapstarted 2014, after this paper: background citation

The Effects of BCG-vaccination on the Innate Immune Response in Healthy Volunteers. Pilot Proof-of-principle Studie

TypeinterventionalSponsorRadboud University Medical CenterRan2014 to 2014Enrolled20ConditionsSepsisArmsBCG vaccine, Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously
NCT04348370 phase4completednot on this mapstarted 2020, after this paper: background citation

Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses

TypeinterventionalSponsorTexas A&M UniversityRan2020 to 2023Enrolled659ConditionsCoronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified ElsewhereArmsBCG Vaccine, Placebo Vaccine
NCT04362124 phase3withdrawnnot on this mapstarted 2020, after this paper: background citation

Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection in Medellín, Colombia, 2020

TypeinterventionalSponsorUniversidad de AntioquiaRan2020 to 2021Enrolled0ConditionsCOVID-19Armsvaccine BCG, Placebo
NCT04379336 phase3completednot on this mapstarted 2020, after this paper: background citation

Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial

TypeinterventionalSponsorTASK Applied ScienceRan2020 to 2022Enrolled1,000ConditionsCOVID-19, Sars-CoV2ArmsBacille Calmette-Guérin (BCG), Placebo Comparator
NCT04383925 phase4completednot on this mapstarted 2020, after this paper: background citation

Randomized Trial Evaluating the Non-specific Effects of Different BCG Strains in Guinea-Bissau: Effects on Early-life Mortality and Morbidity

TypeinterventionalSponsorBandim Health ProjectRan2020 to 2022Enrolled16,390ConditionsDeath, Infant, Morbidity, InfantArmsBCG-Japan, BCG-Russia
NCT04534803 phase3withdrawnnot on this mapstarted 2021, after this paper: background citation

Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial

TypeinterventionalSponsorHarvard Medical School (HMS and HSDM)Ran2021 to 2022Enrolled0ConditionsCovid19ArmsBCG Vaccine, Placebo
NCT04632537 phase3withdrawnnot on this mapstarted 2020, after this paper: background citation

Novel Use of an Existing Vaccine (BCG) Alliance: The NUEVA Trial

TypeinterventionalSponsorHenry M. Jackson Foundation for the Advancement of Military MedicineRan2020 to 2021Enrolled0ConditionsCOVID-19ArmsTice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine, Preservative-free saline
NCT04938323 phase2 / phase3withdrawnnot on this mapstarted 2022, after this paper: background citation

Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly (PARITIE)

TypeinterventionalSponsorHarvard Medical School (HMS and HSDM)Ran2022 to 2022Enrolled0ConditionsAcute Respiratory InfectionArmsBCG Vaccine, Placebo
NCT05591339 phase4active not recruitingnot on this mapstarted 2023, after this paper: background citation

Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau

TypeinterventionalSponsorBandim Health ProjectRan2023 to 2029Enrolled200ConditionsDiabetes Mellitus, BCG Vaccination ReactionArmsBCG vaccine (two doses, 4 weeks apart), Saline placebo (Two doses, 4 weeks apart)
NCT07527247 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity

TypeinterventionalSponsorSingapore General HospitalRan2025 to 2029Enrolled40ConditionsImmune System Responses and Trained Immunity After AS01 Administration, Healthy AdultArmsAS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur), Placebo (NaCl 09%, 0.5mL)
3 · Its place in the literature

Who cites it

990 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,674 citations in OpenAlex.

  1. Pooled it
  2. Mucosal immunity and vaccine development.Signal transduction and targeted therapy · 2026
    Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Neutrophils in cancer.Nature reviews. Cancer · 2026
    Review
  8. Trained Immunity in Childhood Vaccination.Acta paediatrica (Oslo, Norway : 1992) · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Monocyte-derived galectin-1Nature immunology · 2026
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. No Association of Prior Administration of Selected Vaccines with Lymphoma Prognosis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  19. The theory of the inflammatory ecosystem.Science China. Life sciences · 2026
    Review
  20. Review

930 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Johanneke KleinnijenhuisDepartment of Medicine, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, The Netherlands.
Jessica Quintin
Frank Preijers
Leo A B Joosten
Daniela C Ifrim
Sadia Saeed
Cor Jacobs
Joke van Loenhout
Dirk de Jong
Hendrik G Stunnenberg
Ramnik J Xavier
Jos W M van der Meer
Reinout van Crevel
Mihai G Netea
Institute of Infection and Immunity · CARadboud University Medical Center · NLBroad Institute · USGGD Amsterdam · NL

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
Systems Biology of Crohn's DiseaseR01DK083756 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI DALY, MARK JOSEPH, XAVIER, RAMNIK J · 2008 to 2011
$1.5M
Genomic Approaches to Host-Pathogen InteractionsR01AI062773 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI XAVIER, RAMNIK J · 2006 to 2009
$1.4M
NIAID NIH HHS AI 062773NIAID NIH HHS R01 AI062773NIDDK NIH HHS DK 043351NIDDK NIH HHS DK 83756NIDDK NIH HHS P30 DK043351NIDDK NIH HHS R01 DK083756
6 · The paper itself

Abstract

Adaptive features of innate immunity, recently described as "trained immunity," have been documented in plants, invertebrate animals, and mice, but not yet in humans. Here we show that bacille Calmette-Guérin (BCG) vaccination in healthy volunteers led not only to a four- to sevenfold increase in the production of IFN-γ, but also to a twofold enhanced release of monocyte-derived cytokines, such as TNF and IL-1β, in response to unrelated bacterial and fungal pathogens. The enhanced function of circulating monocytes persisted for at least 3 mo after vaccination and was accompanied by increased expression of activation markers such as CD11b and Toll-like receptor 4. These training effects were induced through the NOD2 receptor and mediated by increased histone 3 lysine 4 trimethylation. In experimental studies, BCG vaccination induced T- and B-lymphocyte-independent protection of severe combined immunodeficiency SCID mice from disseminated candidiasis (100% survival in BCG-vaccinated mice vs. 30% in control mice). In conclusion, BCG induces trained immunity and nonspecific protection from infections through epigenetic reprogramming of innate immune cells.

Indexed as

Epigenesis, GeneticAdultBase SequenceBCG VaccineB-LymphocytesChromatin ImmunoprecipitationDNA PrimersHistonesHumansMethylationMonocytesNod2 Signaling Adaptor ProteinPolymerase Chain ReactionT-LymphocytesBCG VaccineDNA PrimersHistonesNOD2 protein, humanNod2 Signaling Adaptor Protein

Identifiers

PMID22988082
PMCPMC3491454
OpenAlexW2059403792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 4 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.